Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study

The prevention of chemotherapy‐induced nausea and vomiting was one of the most challenging supportive care issues in oncology, especially to highly emetogenic chemotherapy (HEC). A total of 645 patients were randomized into fosaprepitant group (fosaprepitant/placebo 150 mg d1 in combination with gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, L.Q., Sun, X.C., Qin, S.K., Cheng, Y., Shi, J.H., Chen, Z.D., Wang, Q.M., Zhang, H.L., Hu, B., Liu, B., Zhang, Q.Y., Wu, Q., Wang, D., Shu, Y.Q., Dong, J., Han, B.H., Wang, K.M., Dang, C.X., Li, J.L., Wang, H.B., Li, B.L., Lu, J.G., Zhang, Z.H., Chen, Y.X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697660/
https://www.ncbi.nlm.nih.gov/pubmed/28393417
http://dx.doi.org/10.1111/ecc.12668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697660/
https://www.ncbi.nlm.nih.gov/pubmed/28393417
http://dx.doi.org/10.1111/ecc.12668

Ejemplares similares